logo-loader

Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan

Published: 11:27 10 Jan 2024 EST

Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan

Amarin Corporation rose by more than a quarter on Wednesday after the drugmaker reported preliminary fourth-quarter revenues well ahead of analysts’ expectations.

In a business update ahead of its presentation to a J.P. Morgan Healthcare conference in San Francisco, the company said it expected 4Q revenues of between $72 million and $74 million versus the $62 million pencilled in by Wall Street analysts.

It ended 2023 with cash of $321 million and delivered full-year positive cash flow of roughly $10 million.

The company also announced it plans to initiate a share repurchase program of up to $50 million once it has received shareholder and UK High Court approval.

“We enter 2024 with a number of positives: we have a solid cash position and no debt; our European business is showing early signs of progress following new leadership and a new strategy; our US business continues to retain IPE market leadership and is in a solid position with exclusive contracts to start 2024; and our partners in the Rest of World (ROW) are advancing commercialization and market access efforts,” Amarin president and CEO Patrick Holt commented in a statement.

The company’s shares were 26% higher at $1.22 in late morning trade in New York.

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 48 minutes ago